Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study.
Visco C, Marcheselli L, Mina R, Sassone M, Guidetti A, Penna D, Cattaneo C, Bonuomo V, Busca A, Ferreri AJM, Bruna R, Petrucci L, Cairoli R, Salvini M, Bertù L, Ladetto M, Pilerci S, Pinto A, Ramadan S, Marchesi F, Cavo M, Arcaini L, Coviello E, Romano A, Musto P, Massaia M, Fracchiolla N, Marchetti M, Scattolin A, Tisi MC, Cuneo A, Della Porta M, Trentin L, Turrini M, Gherlinzoni F, Tafuri A, Galimberti S, Bocchia M, Cardinali V, Cilloni D, Corso A, Armiento D, Rigacci L, La Barbera EO, Gambacorti-Passerini C, Visani G, Vallisa D, Venditti A, Selleri C, Conconi A, Tosi P, Lanza F, Candoni A, Krampera M, Corradini P, Passamonti F, Merli F; ITA-HEMA-COV investigators. Visco C, et al. Among authors: sassone m. Blood Adv. 2022 Jan 11;6(1):327-338. doi: 10.1182/bloodadvances.2021005691. Blood Adv. 2022. PMID: 34644385 Free PMC article.
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma.
Ferreri AJM, Calimeri T, Conte GM, Cattaneo D, Fallanca F, Ponzoni M, Scarano E, Curnis F, Nonis A, Lopedote P, Citterio G, Politi LS, Foppoli M, Girlanda S, Sassone M, Perrone S, Cecchetti C, Ciceri F, Bordignon C, Corti A, Anzalone N. Ferreri AJM, et al. Among authors: sassone m. Blood. 2019 Jul 18;134(3):252-262. doi: 10.1182/blood.2019000633. Epub 2019 May 22. Blood. 2019. PMID: 31118164 Free article. Clinical Trial.
Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum.
Ferreri AJM, Sassone M, Miserocchi E, Govi S, Cecchetti C, Corti ME, Mappa S, Arcaini L, Zaja F, Todeschini G, Mannina D, Calimeri T, Perrone S, Ponzoni M, Modorati G. Ferreri AJM, et al. Among authors: sassone m. Blood Adv. 2020 Mar 24;4(6):1013-1019. doi: 10.1182/bloodadvances.2020001459. Blood Adv. 2020. PMID: 32182364 Free PMC article. Clinical Trial.
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial.
Ferreri AJM, Calimeri T, Ponzoni M, Curnis F, Conte GM, Scarano E, Rrapaj E, De Lorenzo D, Cattaneo D, Fallanca F, Nonis A, Foppoli M, Lopedote P, Citterio G, Politi LS, Sassone M, Angelillo P, Guggiari E, Steffanoni S, Tarantino V, Ciceri F, Bordignon C, Anzalone N, Corti A. Ferreri AJM, et al. Among authors: sassone m. Blood Adv. 2020 Aug 11;4(15):3648-3658. doi: 10.1182/bloodadvances.2020002270. Blood Adv. 2020. PMID: 32766857 Free PMC article. Clinical Trial.
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial.
Ferreri AJM, Cattaneo C, Lleshi A, Verga L, Allione B, Facchetti F, Ponzoni M, Foppoli M, Ferrari D, Rigacci L, Pecciarini L, Donadoni G, Fumagalli L, Sassone M, Calimeri T, Rossi G, Spina M, Re A. Ferreri AJM, et al. Among authors: sassone m. Br J Haematol. 2021 Jan;192(1):119-128. doi: 10.1111/bjh.17188. Epub 2020 Oct 21. Br J Haematol. 2021. PMID: 33085777 Free article. Clinical Trial.
Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.
Ferreri AJM, Angelillo P, Erbella F, Cattaneo C, Verga L, Lleshi A, Allione B, Ponzoni M, Facchetti F, Pagani C, Foppoli M, Pecciarini L, Sassone M, Steffanoni S, Flospergher E, Rossi G, Spina M, Re A. Ferreri AJM, et al. Among authors: sassone m. Blood Adv. 2022 Nov 22;6(22):5811-5820. doi: 10.1182/bloodadvances.2022007475. Blood Adv. 2022. PMID: 35580327 Free PMC article.
Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group.
Steffanoni S, Calimeri T, Laurenge A, Fox CP, Soussain C, Grommes C, Tisi MC, Boot J, Crosbie N, Visco C, Arcaini L, Chaganti S, Sassone MC, Alencar A, Armiento D, Romano I, Dietrich J, Itchaki G, Bruna R, Fracchiolla NS, Arletti L, Venditti A, Booth S, Musto P, Hoang Xuan K, Batchelor TT, Cwynarski K, Ferreri AJM. Steffanoni S, et al. Among authors: sassone mc. Br J Haematol. 2022 Nov;199(4):507-519. doi: 10.1111/bjh.18396. Epub 2022 Aug 9. Br J Haematol. 2022. PMID: 35945164 Free PMC article.
IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma.
Pirosa MC, Sassone M, Kiesewetter B, Guillermo AL, Devizzi L, Domènech ED, Tucci A, Mannina D, Merli M, Salar A, Visco C, Esposito F, Bonomini L, Zucca E, Ferreri AJM, Raderer M. Pirosa MC, et al. Among authors: sassone m. Haematologica. 2023 Jun 1;108(6):1671-1675. doi: 10.3324/haematol.2022.281963. Haematologica. 2023. PMID: 36546422 Free PMC article. Clinical Trial. No abstract available.
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma.
Conconi A, Chiappella A, Ferreri AJM, Stathis A, Botto B, Sassone M, Gaidano G, Balzarotti M, Merli F, Tucci A, Vanazzi A, Tani M, Bruna R, Orsucci L, Cabras MG, Celli M, Annibali O, Liberati AM, Zanni M, Ghiggi C, Pisani F, Pinotti G, Dore F, Esposito F, Pirosa MC, Cesaretti M, Bonomini L, Vitolo U, Zucca E. Conconi A, et al. Among authors: sassone m. Blood Adv. 2024 Mar 26;8(6):1541-1549. doi: 10.1182/bloodadvances.2023011251. Blood Adv. 2024. PMID: 38181782 Free PMC article. Clinical Trial.
31 results